Skip to main content
. 2020 Feb 20;52(2):213–226. doi: 10.1038/s12276-020-0383-3

Fig. 5. Future challenges for small-molecule-mediated clinical trials.

Fig. 5

The future direction of personalized medicine is through small molecules. An ex vivo strategy can generate the desired cells through in vitro reprogramming using small molecules, and these cells are then expanded and transplanted into patients (green arrow). The in vivo strategy is to apply a small-molecule combination directly to patients via oral administration or injection (pink arrow).